COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Standard
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study. / Andreoli, Laura; Lini, Daniele; Schreiber, Karen; Parodis, Ioannis; Sen, Parikshit; Naveen, R; Day, Jessica; Joshi, Mrudula; Jagtap, Kshitij; Nune, Arvind; Nikiphorou, Elena; Agarwal, Vishwesh; Saha, Sreoshy; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Velikova, Tsvetelina; Milchert, Marcin; Edgar Gracia-Ramos, Abraham; Cavagna, Lorenzo; Kuwana, Masataka; Knitza, Johannes; Makol, Ashima; Patel, Aarat; Pauling, John D; Wincup, Chris; Barman, Bhupen; Zamora Tehozol, Erick Adrian; Serrano, Jorge Rojas; García-De La Torre, Ignacio; Colunga-Pedraza, Iris J; Merayo-Chalico, Javier; Chibuzo, Okwara Celestine; Katchamart, Wanruchada; Akarawatcharangura Goo, Phonpen; Shumnalieva, Russka; Chen, Yi-Ming; Hoff, Leonardo Santos; El Kibbi, Lina; Halabi, Hussein; Vaidya, Binit; Sazliyana Shaharir, Syahrul; Hasan, A T M Tanveer; Dey, Dzifa; Gutiérrez, Carlos Enrique Toro; Caballero-Uribe, Carlo V; Lilleker, James B; Salim, Babur; Gheita, Tamer; Chatterjee, Tulika; Saavedra, Miguel A; Distler, Oliver; Chinoy, Gabriela Arredondo Hector; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika; COVAD Study Group.
In: RHEUMATOLOGY, Vol. 63, No. 5, 02.05.2024, p. 1341-1351.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
AU - Andreoli, Laura
AU - Lini, Daniele
AU - Schreiber, Karen
AU - Parodis, Ioannis
AU - Sen, Parikshit
AU - Naveen, R
AU - Day, Jessica
AU - Joshi, Mrudula
AU - Jagtap, Kshitij
AU - Nune, Arvind
AU - Nikiphorou, Elena
AU - Agarwal, Vishwesh
AU - Saha, Sreoshy
AU - Tan, Ai Lyn
AU - Shinjo, Samuel Katsuyuki
AU - Ziade, Nelly
AU - Velikova, Tsvetelina
AU - Milchert, Marcin
AU - Edgar Gracia-Ramos, Abraham
AU - Cavagna, Lorenzo
AU - Kuwana, Masataka
AU - Knitza, Johannes
AU - Makol, Ashima
AU - Patel, Aarat
AU - Pauling, John D
AU - Wincup, Chris
AU - Barman, Bhupen
AU - Zamora Tehozol, Erick Adrian
AU - Serrano, Jorge Rojas
AU - García-De La Torre, Ignacio
AU - Colunga-Pedraza, Iris J
AU - Merayo-Chalico, Javier
AU - Chibuzo, Okwara Celestine
AU - Katchamart, Wanruchada
AU - Akarawatcharangura Goo, Phonpen
AU - Shumnalieva, Russka
AU - Chen, Yi-Ming
AU - Hoff, Leonardo Santos
AU - El Kibbi, Lina
AU - Halabi, Hussein
AU - Vaidya, Binit
AU - Sazliyana Shaharir, Syahrul
AU - Hasan, A T M Tanveer
AU - Dey, Dzifa
AU - Gutiérrez, Carlos Enrique Toro
AU - Caballero-Uribe, Carlo V
AU - Lilleker, James B
AU - Salim, Babur
AU - Gheita, Tamer
AU - Chatterjee, Tulika
AU - Saavedra, Miguel A
AU - Distler, Oliver
AU - Chinoy, Gabriela Arredondo Hector
AU - Agarwal, Vikas
AU - Aggarwal, Rohit
AU - Gupta, Latika
AU - COVAD Study Group
AU - Holzer, Marie-Therese
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2024/5/2
Y1 - 2024/5/2
N2 - OBJECTIVES: We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.METHODS: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine.RESULTS: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P < 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively.CONCLUSION: This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
AB - OBJECTIVES: We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.METHODS: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine.RESULTS: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P < 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively.CONCLUSION: This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
U2 - 10.1093/rheumatology/kead382
DO - 10.1093/rheumatology/kead382
M3 - SCORING: Journal article
C2 - 37505460
VL - 63
SP - 1341
EP - 1351
JO - RHEUMATOLOGY
JF - RHEUMATOLOGY
SN - 1462-0324
IS - 5
ER -